drugset / Trial / NCT01668511

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee

NCT01668511

Phase 1 Completed 36 enrolled AbbVie
RandomizedParallel-groupTriple-blindTreatment

Summary

To assess the safety, tolerability and pharmacokinetics of ABT-981 in patients with osteoarthritis of the knee.

Timeline

Start
2012-09
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lutikizumab Monoclonal antibody 0.3 mg/kg Subcutaneous
Subject Lutikizumab Monoclonal antibody 1 mg/kg Subcutaneous
Subject Lutikizumab Monoclonal antibody 3 mg/kg Subcutaneous

Indications